DarioHealth (NASDAQ:DRIO) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of DarioHealth (NASDAQ:DRIO) from a hold rating to a sell rating in a report issued on Sunday morning.

DRIO has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of DarioHealth in a research report on Monday, December 29th. Stifel Nicolaus set a $16.00 target price on shares of DarioHealth in a report on Friday, November 14th. Finally, TD Cowen restated a “hold” rating on shares of DarioHealth in a research note on Friday, November 14th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, DarioHealth presently has an average rating of “Hold” and a consensus price target of $32.00.

DarioHealth Price Performance

DRIO stock opened at $10.91 on Friday. DarioHealth has a 52-week low of $5.93 and a 52-week high of $17.74. The company has a quick ratio of 4.02, a current ratio of 4.55 and a debt-to-equity ratio of 0.41. The stock has a market cap of $73.72 million, a price-to-earnings ratio of -0.98 and a beta of 1.05. The business has a fifty day moving average of $11.89 and a two-hundred day moving average of $11.93.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in DarioHealth stock. XTX Topco Ltd grew its position in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 62,511 shares of the company’s stock after purchasing an additional 43,513 shares during the quarter. XTX Topco Ltd owned approximately 0.14% of DarioHealth worth $42,000 at the end of the most recent reporting period. Institutional investors own 33.39% of the company’s stock.

About DarioHealth

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.